相关实验视频
Updated: Jul 9, 2025

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
注册的COVID-19临床试验的传播 (DIRECCT):一个横截面研究
Maia Salholz-Hillel1, Molly Pugh-Jones1, Nicole Hildebrand1
1QUEST Center for Responsible Research, Berlin Institute of Health (BIH), Charite Universitätsmedizin Berlin, Berlin, Germany.
报告COVID-19临床试验结果显著滞后,大多数试验没有达到12个月的标准. 预印件有助于传播,但试验注册表未被充分利用,无法及时报告.
科学领域:
- 临床研究方法论临床研究方法论
- 公共卫生应急响应公共卫生应急响应
- 流行病学 流行病学
背景情况:
- 在COVID-19等公共卫生紧急情况期间,快速报告临床试验结果至关重要.
- 这项研究调查了COVID-19临床试验结果传播的及时性和道.
研究的目的:
- 检查COVID-19临床试验结果传播时间表和方法.
- 评估报告率并确定影响传播速度的因素.
主要方法:
- 从世卫组织ICTRP数据库中确定了COVID-19治疗/预防试验,完成日期为2021年6月30日.
- 搜索了多个数据库 (PubMed,谷歌学者等) 对于已发表的结果 (预印件,文章,注册表条目).
- 分析了使用卡普兰-梅尔方法完成到报告的传播率和时间.
主要成果:
- 包括1643个试验;累计报告概率为12.5%在3个月后,21.6%在6个月后,32.8%在12个月后完成.
- 期刊是最常见的传播途径 (69.2%),其次是 preprints (48.3%).
- 早期的试验和涉及ivermectin的试验显示报告速度更快;注册表数据质量准确性有限.
结论:
- COVID-19试验报告显示,与标准实践相比,试验的改善只是微不足道的,大多数试验未能达到12个月的基准.
- 预印件补充了期刊出版物,但临床试验注册表在快速传播结果方面未得到充分利用.
- 在全球,国家和机构层面上,提高注册表数据质量和强调快速报告至关重要.
更多相关视频
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
相关概念视频
Clinical Trials
There are four phases in a clinical trial. A phase one...
Hazard Ratio
For example, in a clinical trial...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Statistical Software for Data Analysis and Clinical Trials
Real Time RT-PCR
The real-time quantification of the number of amplified products is...
Targeted Cancer Therapies
There are several types of targeted therapies against...